Egetis Therapeutics

Company Description

---

Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.

The Company’s lead candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a long-term real-life study) Emcitate has shown highly significant and clinically relevant results on serum T3 levels and secondary clinical endpoints. As a result of fruitful regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) in the first half of 2023 based on existing clinical data.

Year founded

---

2006

Headquarters

---

Klara Norra Kyrkogata 26, 11122 Stockholm – Sweden

Shares outstanding

---

214,589,128

IPO

---

Oct. 31, 2019

Stock exchange(s)

---

Nasdaq Stockholm